Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 20 citing articles:

Nuclear transport proteins: structure, function, and disease relevance
Yang Yang, Lu Guo, Lin Chen, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 56
Selinexor: Targeting a novel pathway in multiple myeloma
Clifton C. Mo, Andrew J. Yee, Shonali Midha, et al.
eJHaem (2023) Vol. 4, Iss. 3, pp. 792-810
Open Access | Times Cited: 15
Selinexor in multiple myeloma
Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, et al.
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 4, pp. 421-434
Closed Access | Times Cited: 5
Multiple myeloma refractory to lenalidomide: A systematic literature review of trials and real‐world evidence
Monique Hartley-Brown, Katja Weisel, Jacopo Bitetti, et al.
British Journal of Haematology (2024) Vol. 205, Iss. 3, pp. 780-797
Open Access | Times Cited: 5
Targeting deubiquitinase USP7-mediated stabilization of XPO1 contributes to the anti-myeloma effects of selinexor
Junying Wang, Mengping Chen, Jinxing Jiang, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
Nuclear to Cytoplasmic Transport Is a Druggable Dependency in HDAC7‐driven Small Cell Lung Cancer
Tingting Qin, Jingya Wang, Jian Wang, et al.
Advanced Science (2025)
Open Access
Safety assessment of selinexor: a real-world pharmacovigilance study
Wei Zhang, Kai Tao, Bin Zeng, et al.
Expert Opinion on Drug Safety (2025)
Closed Access
Treatment of Multiple Myeloma in Patients Refractory to Daratumumab/Anti‐CD38 Monoclonal Antibodies: A Systematic Review
Chia Jie Tan, Dylan Kacerek, Nattawara Kampirapawong, et al.
Cancer Medicine (2025) Vol. 14, Iss. 5
Open Access
Adverse events reporting of XPO1 inhibitor - selinexor: a real-word analysis from FAERS database
Yi Liu, Runyu Yang, Hui Feng, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 4
Lipin1-dependent transcriptional inactivation of SREBPs contributes to selinexor sensitivity in multiple myeloma
Junying Wang, Minfeng Chen, Jifeng Jiang, et al.
Acta Pharmacologica Sinica (2025)
Open Access
Recent Advances in the Applications of Small Molecules in the Treatment of Multiple Myeloma
H. N. Abramson
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2645-2645
Open Access | Times Cited: 9
RNA-binding protein hnRNPU regulates multiple myeloma resistance to selinexor
Xin Wang, Juan Xu, Qun Li, et al.
Cancer Letters (2023) Vol. 580, pp. 216486-216486
Closed Access | Times Cited: 7
Treatment of multiple myeloma with selinexor: a review
Qianlei Huang, Ranran Zhao, Lu Xu, et al.
Therapeutic Advances in Hematology (2024) Vol. 15
Open Access | Times Cited: 2
The numerous facets of 1q21+ in multiple myeloma: Pathogenesis, clinicopathological features, prognosis and clinical progress (Review)
Na Liu, Zhanzhi Xie, Hao Li, et al.
Oncology Letters (2024) Vol. 27, Iss. 6
Open Access | Times Cited: 2
Real-world outcome of patients with extensively pretreated multiple myeloma who were treated with selinexor and dexamethasone: a Korean multicenter retrospective analysis
Jun Ho Yi, Sung‐Soo Park, Chang‐Ki Min, et al.
Annals of Hematology (2024) Vol. 103, Iss. 7, pp. 2365-2372
Closed Access | Times Cited: 1
Efficacy and safety of selinexor for patients with relapsed and refractory multiple myeloma: A meta-analysis
Laila Shafei, S. Bashir, Esther W. Chan, et al.
Current Problems in Cancer (2024) Vol. 50, pp. 101076-101076
Closed Access
Cytidine triphosphate synthase 1-mediated metabolic reprogramming promotes proliferation and drug resistance in multiple myeloma
Hanying Huang, Yanzhou Chen, Yang Li, et al.
Heliyon (2024) Vol. 10, Iss. 13, pp. e33001-e33001
Open Access
Efficacy, safety, and pharmacokinetics of teclistamab in Chinese patients with relapsed/refractory multiple myeloma from the China cohort of MajesTEC‐1
Zhen Cai, Zhongjun Xia, Aili He, et al.
Cancer (2024)
Open Access
Targeting XPO1 for fighting relapsed/refractory diseases: The research progress of XPO1 inhibitors
Yingchun Li, Fang Zhou, Wen Zhang, et al.
Bioorganic Chemistry (2024) Vol. 154, pp. 108073-108073
Closed Access
Rediscovering hemostasis abnormalities in multiple myeloma: The new era
Yudie Huang, Chongyu Wang, Hua Wang, et al.
Heliyon (2024) Vol. 10, Iss. 13, pp. e34111-e34111
Open Access
Re: CARTIFAN-1: Concerning fatal adverse events with global use of chimeric antigen receptor–T-cell therapy in multiple myeloma
Jian‐Qing Mi, Wanhong Zhao, Hongmei Jing, et al.
European Journal of Cancer (2023) Vol. 188, pp. 108-110
Closed Access
Page 1

Scroll to top